Histone deacetylase inhibitor and chemotherapy combined effect on Raji Burkitt's lymphoma cell line
Summary:
Analysis of Raji Burkitt's lymphoma (BL) cell line treated with histone deacetylase inhibitor HDACi (sodium butyrate, NaB) or chemotherapy (VP-16) or both for 24 hours. Results provide insight into the molecular effects of combined HDACi/VP-16 therapy of this aggressive B-cell lymphoma.
GPL4133:
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Feature Number version)
Citation:
Ferreira AC, Robaina MC, Rezende LM, Severino P et al. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Ann Hematol 2014 Jun;93(6):983-93. PMID: 24577510
